This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is Daratumumab.
The trial is open at the Dana Farber Cancer Institute, run by Dr. Irene Ghobrial, a myeloma specialist with a focus on precursor conditions. It is also open at Beth Israel Deaconess Medical Center in Boston.
To learn more about this trial and sign up to receive notifications, click here:Study of the CD38 Antibody Daratumumab Clinical Trial
To find all eligible clinical trials, click here:Study of the CD38 Antibody Daratumumab Clinical Trial